Editas announcement
Web13 apr. 2024 · 14 analysts have issued twelve-month price targets for Editas Medicine's stock. Their EDIT share price forecasts range from $7.00 to $35.00. On average, they expect the company's stock price to reach $15.33 in the next year. This suggests a possible upside of 128.5% from the stock's current price. View analysts price targets for EDIT or view ... Web14 jun. 2024 · CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it named Chi Li, Ph.D., MBA, RAC, as the...
Editas announcement
Did you know?
Web31 mrt. 2024 · Editas Medicine closed an underwritten offering of 4,025,000 shares of its common stock at a public offering price of $66.00 per share, before deducting … Web13 apr. 2024 · CAMBRIDGE, Mass., April 13, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced the appointment of current Independent Director Emma Reeve as Chair of the Board, effective at the Company’s next annual stockholder meeting, currently scheduled for June 1. Ms.
Web24 mrt. 2024 · Editas Medicine, Inc. Announces That James C. Mullen, the Executive Chairman of the Board of Directors Will Not Stand for Re-Election as A Director: CI. 03/08: Editas Medicine Strengthens Executive Leadership Team with Appointment of Linea Aspesi as Chief People Officer: GL. Summary: Quotes: Charts: News: Ratings: Calendar: Web17 nov. 2024 · CAMBRIDGE, Mass., Nov. 17, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced clinical …
WebEditas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, and precise genomic medicines for a broad class of diseases. Our corporate headquarters is located in Cambridge, MA, and we have a significant and growing site in Boulder, CO. We are pioneering the possibilities of genomic medicines through gene ... Web17 nov. 2024 · Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial November 17, 2024 07:15 ET Source: Editas Medicine, Inc. Editas Medicine, Inc.
Web12 apr. 2024 · Apr 12, 2024 11:47AM EDT Editas Medicine, Inc. EDIT announced that it has dosed the first pediatric patient in the phase I/II BRILLIANCE study evaluating its lead candidate, EDIT-101, for the...
Web6 dec. 2024 · Editas Is Cash Rich In its last set of earnings (Q322) Editas reported a cash position of $479m and a net loss of $55.7m for the quarter, and net loss of $160m for the first three quarters of... dates coachellaWeb1 dag geleden · Editas Medicine , Inc. (Nasdaq: NASDAQ:EDIT), a clinical stage genome editing company, today announced the appointment of current Independent Director Emma Reeve as Chair of the... massive resistance 1954Web18 aug. 2024 · Say the company announces EPS of $0.80, beating expectations by 6.7%, yet investors respond by selling shares. While the news was "good," perhaps investors expected more. massive retaliation apushWeb4 aug. 2024 · Editas had cash, cash equivalents and investments worth $527.6 million as of Jun 30, 2024 compared with $566.4 million as of Mar 31, 2024. Shares of Editas were up 13.4% on Wednesday following the announcement of the earnings result. The stock has plunged 29.6% in the year compared with the industry’s decrease of 22.1%. date scones donna hayWeb4 mei 2024 · Editas Medicine is developing EDIT-101 for the treatment for Leber Congenital Amaurosis 10 (LCA10), a CEP290-related retinal degenerative disorder. Previously … massive resistance movementWeb10 dec. 2024 · Leading genome editing company Editas Medicine, Inc. EDIT announced that it submitted an Investigational New Drug (IND) application to the FDA for the initiation of a phase I/II study of EDIT-301. dates copernicWeb20 jan. 2024 · The biggest setback was Editas’ announcement in November 2024 that it was pausing development of its lead clinical program EDIT-101, which was being evaluated in the phase 1/2 BRILLIANCE trial (NCT03872479) after disappointing efficacy in treating Leber congenital amaurosis 10. 2 Another trial, the RUBY trial (NCT04853576) of EDIT-301 for … dates coachella 2022